Prerpints.org logo
Preprint
Review

Respiratory Syncytial Virus Vaccines: Analysis of the Pre-Marketing Clinical Trial for Immunogenicity in the Population over 50 Years of Age

Altmetrics

Downloads

175

Views

62

Comments

0

A peer-reviewed article of this preprint also exists.

supplementary.pdf (57.65KB )

Submitted:

20 February 2024

Posted:

20 February 2024

You are already at the latest version

Alerts
Abstract
Immunosenescence refers to age-related alterations of the immune system function affecting both the humoral and cellular arm of immunity. Understanding immunosenescence and its impact on vaccination of older adults is essential since primary vaccine responses in older individuals can fail to generate complete protection, especially vaccines targeting infections with increased incidence among the elderly, such as the respiratory syncytial virus. Here, we review the clinical trials of both candidate and approved vaccines against respiratory syncytial virus (RSV), which include adults aged ≥50 years, with an emphasis on the evaluation of immunogenicity parameters. Currently, there are 10 vaccine candidates and 2 vaccines approved for the prevention of RSV in the older adult population. The number of registered clinical trials for this age group amounts to 32. Our preliminary evaluation of published results and interim analyses of the RSV vaccine clinical trials indicates efficacy in older adult participants, demonstrating immunity levels that closely resemble those of younger adult participants.
Keywords: 
Subject: Medicine and Pharmacology  -   Medicine and Pharmacology

1. Introduction

Aging is extensively researched because of the population's constantly increasing and anticipated lifespan. According to the World Health Organization (WHO), a two-fold growth of the population over 60 years of age is expected by the year 2050, reaching 2.1 billion people. Interestingly, the increase mentioned above is expected to include a significant proportion of the population in low- and middle-income countries. [1] Significantly, viral and bacterial infections reduce the overall health in this population due to disease resulting from alterations in the immune system following aging. [2] The term “immunosenescence” describes the sequence of immune system adaptations occurring with advanced age [3,4,5]. As a result, the elderly population responds in a downmodulated manner to pathogen exposure as compared to the younger population. At the same time, concomitantly, autoimmunity and the development of malignancies are also associated with immune dysregulation. [3] Older individuals are considered to be in a state of chronic pro-inflammation due to the dysregulation of the immune system and a decreased elimination of antigens, scientifically known as “inflammaging”. [6,7] Inflammaging is mediated through cells developing a senescence-associated secretory phenotype (SASP), which triggers low-grade immunity [8,9,10,11]. A multifaceted attribute orchestrates this chronic inflammation process, shaped by environmental and metabolic factors [8]. Noteworthy is the influence of advancing age, which extends to both parts of the immune response, innate and adaptive immunity [11], and immune remodeling leads to the development of systematic diseases, raises the risk of infections, and can differentiate the antibody response to vaccinations. [6,12]

1.1. Innate Immunity

Toll-like receptors (TLRs) are expressed on phagocytic cells, mediating significant processes related to innate immunity. Dysfunction and altered expression of TLRs appear to be present in the late years of life. [8] By analyzing phagocytic cells, older individuals were observed to maintain the same number of total monocytes, myeloid dendritic cells (DCs), and neutrophils as younger adults. However, plasmacytoid DCs, which are involved, among others, in responses against viruses and autoimmune responses, decrease in number. [8,13] Alterations in the functionality of phagocytic cells with imbalanced release of cytokines is seemingly a critical factor in the differentiated innate immune response to pathogens [8]. Phagocytosis and the presentation capacity of antigens by DCs also seem weakened. [8] Natural killer (NK) cells are less cytotoxic in the older adult population due to differentiation of specific subsets and display alterations in cytokine release. [14] Overall, the innate immune system dysfunction results in an impaired adaptive immune system activation.

1.2. Adaptive Immunity

1.2.1. T Cell Immunity

Thymic degeneration and dysfunctional release of cytokines by thymic cells occurring during aging directly impact the number of new circulating naïve T cells and affect, to a greater extent, CD8+ T cells. [15] However, hematopoietic stem cells (HSC) in the bone marrow remain functional and stable in number with aging. [16] Concomitantly, senescent T cells with an extended duration of life and an impaired ability to replicate an increase in peripheral tissues constrain the immune system’s capacity to respond to new antigens adequately. [15] Some effector T cells, rather than developing into memory cells, transition into either a senescent or exhausted state, which can alter vaccine-induced immunity. [17] It is shown that the initiation of immune responses from the T cell antigen receptor (TCR) is modified in CD4+ T cells, including the down-regulation of target genes in older human cells and increased expression of genes encoding pro-inflammatory cytokines. [18] An inversely proportional relationship between Th17 and Treg cells, with Th17 cells increasing during age, suggests a possible explanation for the chronic inflammatory state in elderly individuals. [19]

1.2.2. B Cell Immunity

Similar to T cells, naïve B cells experience a numerical decline in the elderly [13]. B cell repertoire decreases in heterogeneity, especially in people with a reduced general health status. [13,20] Furthermore, the expression of variable B cell receptors (BCRs) is constrained with aging. Additionally, antibodies synthesized from B cells against different antigens show a decreasing trend. [8]
Considering these notable alterations in the immune system of the elderly, variations in the responses to vaccination would be anticipated within the older adult population. Nevertheless, progress in understanding the immune alterations related to aging led to new vaccination approaches to generate higher levels of immunity, as is the case of influenza vaccination [21,22]. Similarly, new vaccines against Streptococcus, herpes zoster, and COVID-19 effectively induce antibody production and memory immunity in the senior population. [17] Currently, the Centers for Disease Control and Prevention of the United States (CDC) advises vaccination against COVID-19, influenza, pneumococcal disease, herpes zoster, tetanus, diphtheria, and whooping cough for adults 65 years or older. [23] Additionally, vaccination against respiratory syncytial virus (RSV) was recently approved and suggested for adults aged 60 years or older, based on individualized medical evaluation. [23] RSV infection markedly elevates morbidity and mortality rates among the elderly. Lower diagnosis rates of RSV infection are observed in adults, leading to an undervaluation of the actual disease impact. [24,25,26] Considering the burden of RSV infection in the elderly, several vaccine candidates, some targeting different antigens, have been tested in clinical trials, ensuring multiple approaches in developing protective RSV vaccines for the elderly. Importantly, RSV vaccine research is undergoing significant expansion after the recent market release of two subunit vaccines protecting against RSV-associated lower respiratory tract disease (LRTD) in the elderly population aged 60 years or older, evidencing that vaccines against this pathogen can be achieved after more than six decades of research.
In a previous review, we assessed the development of RSV vaccines, encompassing all age target groups and associated outcomes [27]. Here, we present a narrative review of the clinical trials of both candidate and approved vaccines against RSV, which include adults aged ≥50 years, with an emphasis on the evaluation of immunogenicity parameters. This study aims to investigate the immune responses to RSV vaccines within the elderly population, considering the physiological processes of immunosenescence and inflammaging that contribute to altered immune responses.

2. Materials and Methods

We conducted searches in the Cochrane Database, MEDLINE database (PubMed), ClinicalTrials.gov clinical trial registry, and the WHO International Clinical Trials Registry Platform (ICTRP). Additionally, we extracted data from the European Medicines Agency (EMA), the Centers for Disease Control and Prevention of the United States (CDC), and the U.S. Food and Drug Administration (FDA), as well as from the official websites of pharmaceutical companies forming the RSV vaccine landscape. The search terms for this study included variations of “respiratory syncytial virus”, “vaccine”, “elderly”, and “clinical trial”. The last update of the literature research was on 27 December 2023. A modified PRISMA flow diagram of the research process is presented in the supplementary materials (File S1: Modified PRISMA flow diagram). The inclusion criteria comprised clinical trials testing an RSV vaccine candidate or already approved vaccine, enrolling an adult population aged 50 years and above. Clinical trials of candidates in the early stages of development in younger adults were also incorporated in the review, under the stipulation that inclusion depended on the company’s intention for market approval as a vaccine for older adults. Variables of interest were the vaccine type and the antigen used, the age group of the participants, and the immunization responses. The exclusion criteria included preclinical phases of development, passive immunization drugs, and clinical trials of the vaccines in different populations. In the following section, a detailed report of the results is presented.

3. Results

A summary of the results is presented in Table 1.

3.1. mRNA Vaccines

3.1.1. mRNA-1345

mRNA-1345, developed by Moderna, Inc., is under evaluation by the regulatory authorities. The company announced in July 2023 the submission of data from the clinical trials for vaccine licensure to the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia. [49] The results from the Phase I clinical trials (NCT04528719, NCT05397223, NCT05585632) in the older adult participants indicate immunity induction in this age group. Specifically, in the NCT04528719 study, the geometric mean fold rises (GMFR) 1 month after vaccination were 12.1-16.6 and 8.7-12.6 for the RSV-A and RSV-B neutralizing antibodies, respectively. Reduced GMRF was measured at 6 months and maintained at a minimum level of 4.1. The levels of pre-fusion (PreF) binding antibody GMFRs followed a similar pattern. These measurements were analogous to the measurements of the younger groups. [28] ConquerRSV (NCT05127434) further tested mRNA-1345 in adults ≥60 years old as a Phase II/III clinical trial. The vaccine efficacy (VE) reached a rate of 83.7% protection against RSV-LRTD, defining the disease with at least two symptoms. Using the definition of three or more symptoms for RSV-LRTD, the VE did not show a substantial difference, with a rate of 82.4%. The study further evaluates the participants' responses and expects new analyses. [49] Finally, RSVictory (NCT05330975), another Phase III trial, assesses mRNA-1345 in adults ≥50 years old. Moderna recently initiated a Phase III trial (NCT06067230) to test the vaccine in adults 18 years or older with high-risk comorbidities for RSV severe infection. Co-administration of this vaccine with a quadrivalent influenza vaccine for individuals aged 65 years or older is also ongoing as a Phase III clinical study (NCT06060457).

3.1.2. RSV mRNA LNP CL-0059/RSV mRNA LNP CL-0137

Sanofi Pasteur introduced a candidate vaccine for older individuals using also the mRNA technology. The vaccine is delivered through one of the two lipid nanoparticles (LNPs), namely LNP CL-0059 or LNP CL-0137. Enrolling a total of 790 participants of two age groups -both younger and older adults- the Phase I/II study (NCT05639894) is anticipated to be completed by 2026.

3.2. Subunit/ Viral-Like-Particle (VLP)-Based Vaccines

3.2.1. IVX-A12

The IVX-A12 candidate from Icosavax, Inc. is a virus-like particle (VLP)-based vaccine, composed of two partial vaccines IVX-121 and IVX-241, against RSV and the human metapneumovirus (hMPV), respectively. The F protein in its stabilized prefusion form is the antigen used with the addition of MF59, an oil-in-water emulsion, as the adjuvant. The Phase I clinical trial (NCT05664334) recruited individuals aged 60 to 75 years. The evidence of a prespecified analysis indicates an immunologically feasible combination of the antigens as a single vaccine form. One month after vaccination, there was an approximately sixfold increase in the geometric mean titers (GMTs) of RSV-A neutralizing antibodies and a threefold increase for RSV-B, compared to the titers of the placebo recipients. The GMFR reached up to fourfold for RSV-A and 3-fold for RSV-B with similar results for the hMPV antibody titers. [30] After these results, the company announced a Phase II clinical trial (NCT05903183), having already enrolled 264 adults 60 to 85 years of age. Recently, the company shared the interim data from this trial. A substantial elevation, approximately sixfold, in the titers of neutralizing antibodies specific to the RSV-A strain and, concomitantly, a fourfold elevation for the RSV-B strain were reported. The results for the hMPV were similarly promising. [31]

3.2.2. DPX-RSV(A)

Immunovaccine Technologies, Inc. has developed a subunit vaccine based on the RSV-A small hydrophobic (SH) protein, specifically the extracellular domain of the protein, representing a new approach that diverges from targeting the F protein as an antigen of interest. In Phase I, a first-in-human study (NCT02472548), participants aged 50-64 years of age were stratified into different dose groups. The immunogenicity outcomes for this novel antigen were encouraging. Specifically, vaccines exhibited a tenfold increase in the geometric mean antibody titer ratio at two months. Further, at day 236, they demonstrated nearly a one hundredfold increase of the GMTR in the participants receiving the vaccine. Immunogenicity was not achieved for the placebo recipients, and they were adjuvanted with the Alum formulation. The antibody elevation was observed for up to 180 days following the second dose. High levels of immunogenicity were achieved for this age group of 50-64 year old participants. [32] The activation of humoral immunity following vaccination reaches a level comparable to that observed after natural exposure to the virus. [50]

3.2.3. VN-0200

Daiichi Sankyo Co. created VN-0200 against RSV and is currently conducting a Phase II clinical trial (NCT05547087) in adults in Japan in the age range of 60-80 years. The Phase I study (NCT04914520) is already completed, including a wide age range of young and older adults. The antigen of interest is stated as VAGA-9001a, and the adjuvant is MABH-9002b. However, the company did not disclose the specific antigen and adjuvant. Information on the results is not currently published.

3.2.4. BARS13 (ADV110)

BARS13, manufactured by Advaccine Biopharmaceuticals Co., displays RSV G protein as the antigen co-administered with cyclosporine A as the adjuvant. [51,52] Evaluation of the vaccine in younger adults aged 18-45 years in a Phase I clinical trial (NCT04851977) revealed a dose-dependent induction of immunity regarding specific antibodies against RSV-G protein. [51] Subsequently, a Phase II study (NCT04681833) followed to assess the vaccine in older adults aged 60-80 years. The enrollment is completed with 125 individuals, and the expected completion date is 2024.

3.2.5. DS-Cav1 (VRC-RSVRGP084-00-VP)

DS-Cav1 was developed by the National Institute of Allergy and Infectious Diseases (NIAID) with the aim of inducing immunity against the preF protein of RSV. Modifications have led to the stable form of the preF protein. [53,54] The vaccine was successfully tested in a Phase I clinical trial (NCT03049488) in adults 18-50 years of age. Evidence of immunity arose for the participants receiving the unadjuvanted formulation. Dose-dependent production of neutralizing antibodies for both RSV strains was measured until week 44. Interestingly, mucosal immunity was also activated. One of the vaccine’s target age groups is older adults. [33] Various modifications were subsequently tested to achieve elevated levels of immunity. [55,56,57]

3.2.6. Arexvy™

Arexvy™, by GlaxoSmithKline (GSK) plc., is the first vaccine to receive authorization from the FDA for public use. This vaccine was indicated for adults aged 60 years or older and aims to protect this population from lower respiratory tract disease related to RSV infection. [58] Subsequently, the EMA and Medicines and Healthcare Products Regulatory Agency (MHRA) provided a market licensure for the vaccine with the same indication. [59,60] The target antigen is the RSV F protein at the stable prefusion form delivered with the adjuvant system 01 (AS01E) to enhance the immune response. The initial assessment in two Phase I clinical trials (NCT03814590, NCT04090658) included adults aged 60-80 years old. Higher titers of specific IgG antibodies, neutralizing antibodies, and CD4+ T cells were measured after vaccination with peak titers on day 31. Maintenance until a year after immunization was noted. Cell-mediated immunity activation is an important focus for older adults. [34,35] A Phase II study (NCT04657198) was designed as an extension trial of the previous Phase I NCT03814590, revaccinating the older adult participants of the initial study 18 months after the last vaccination on the parent study. Following the initial trial, the responses endured with a diminished intensity until the revaccination. Subsequent to revaccination, a notable increase in specific IgG and neutralizing antibodies, accompanied by the further reactivation of CD4+ T cell immunity, was described. These results signify the enhancing impact of a revaccination schedule in older adults. [36] A Phase IIb open-label clinical trial (NCT05921903) is actively enrolling individuals 50 years of age or older. The trial aims to assess responses in patients deemed at high risk for RSV-associated lower respiratory tract disease. A total number of nine Phase III clinical trials (NCT04732871, NCT04841577, NCT04886596, NCT05059301, NCT05559476, NCT05568797, NCT05590403, NCT05966090, NCT05879107) are registered. The results from the NCT04732871 trial until month 6 were similar to those of the previous studies, with high levels of humoral and cellular immunity, lasting above the baseline titers until month 6. [37] The NCT04886596 Phase III clinical trial enrolled 24,966 participants aged 60 years or older. The measured vaccine efficacy in this trial demonstrated an 82.6% efficacy against RSV-associated lower respiratory tract disease, augmenting to 94.1% for severe cases of RSV-associated lower respiratory tract disease. Additionally, an efficacy rate of 71.7% was reported for the outcome of one or more RSV-associated acute respiratory infection episodes. No significant differences were observed between adults 60-69 and 70-79 years and adults with comorbidities. Specifically, the vaccine efficacy was estimated at 93.8% for the age group of 70-79 years, 92.9% for the vaccinees with a pre-existing condition of frailty, and 94.6% for the participants with comorbidities. The authors highlighted that responses in adults 80 years or older and frail individuals need a cautious examination. [39] The study is presently in progress.

3.2.7. Abrysvo™

Abrysvo™ is also authorized by the FDA and EMA, sharing the same indication as Arexvy™ for adults aged 60 years or older. Pfizer Inc. developed the vaccine as a bivalent subunit candidate encoding the RSV F protein in the stabilized preF form from both RSV strains. [61,62] The first-in-human clinical trial (NCT03529773) for Abrysvo™ included 1,235 younger and older adult participants. The positive immunogenicity outcomes, characterized by elevated antibody titers against both RSV A and RSV B and specific IgG titers, indicated a sustained immunity that, although diminishing, remained above baseline up to 12 months post-vaccination. [41] These results manifested to a comparable extent in younger and older adult participants. [40] A Phase Ib co-administration study (NCT05788237), with another vaccine candidate targeting influenza, was recently completed, but the results have not been announced. In the Phase II development stage, the studies included non-pregnant and pregnant women (NCT04071158, NCT04032093) and younger adults in an RSV challenge study (NCT04785612). Within the framework of this controlled viral exposure protocol, the vaccine exhibited effectiveness regarding the manifestation of clinical symptoms associated with RSV disease. [42] A Phase III clinical trial (NCT04424316) in pregnant women has recently been completed. RENOIR (NCT05035212), an active Phase III clinical trial, has enrolled 37,633 adults 60 years and older. A primary analysis of the data until July 2022 was published. The efficacy was determined to be 66.7% in preventing RSV-related lower respiratory tract illness characterized by the presence of at least two or more symptoms. This efficacy rate increased to 85.7% for the cases of illness with at least three or more symptoms. The corresponding rate for the acute illness was 62.1%. The vaccine was protective throughout the entire RSV season. Furthermore, specific analyses were conducted across three age groups (60-69 years, 70-79 years, and ≥80 years) and among individuals categorized as high risk for illness. The results were encouraging, revealing no significant differences in the responses across the groups. It remains to be clarified whether the responses can be sustained across subsequent RSV seasons in order to determine the vaccination schedule. Additionally, further investigation is required to ascertain the nature of responses in individuals with an immunodeficiency state. [43] In a separate Phase III clinical trial (NCT05096208), three lots of the vaccine underwent testing in younger adults. A Phase III trial (NCT05301322) involving co-administration with the seasonal inactivated influenza vaccine was recently completed. MONET (NCT05842967) is an active Phase III trial that has already enrolled 858 adults with a high-risk condition of developing severe illness. Two sub-studies are planned, including individuals aged at least 60 years.

3.2.8. BLB-201

Blue Lake Biotechnology's candidate vaccine BLB-201 is based on the full-length RSV-F protein, is administered through the nasal route, and utilizes the viral live attenuated vector parainfluenza virus type 5 (PIV5). [63,64] In an early Phase I study (NCT05281263), BLB-201 underwent testing across two age groups, adults aged 18-59 and 60-75. BLB-201 effectively boosted the specific serum and mucosal antibody production in both age groups. Mucosal immune response was activated to a greater extent in younger participants, suggesting a potential adjustment in dosage or administration schedule for the elderly. Interestingly, older adult participants showed strong cytotoxic CD8+ T cell immunity. [46] A Phase I/II study (NCT05655182) was also initiated for the pediatric population.

3.2.9. rBCG-N-hRSV

Investigators at the Pontificia Universidad Católica de Chile created rBCG-N-hRSV, a recombinant vaccine using a live attenuated Mycobacterium bovis bacillus Calmette-Guérin (BCG) platform. The antigen expressed through BCG is the nucleoprotein N of RSV. [65,66,67] The incorporation of this combination provides the benefit of a bivalent vaccine. [66] The first-in-human Phase I clinical trial included younger adults until the age of 50 years. Following vaccination, elevated levels of specific antibodies against both antigens were observed, with a more pronounced effect observed in participants who received the highest dose. [47] Additional analyses regarding immunogenicity aspects were conducted, enhancing the positive data from the Phase I trial in younger adults. Assessment of the results helps further the planning of the upcoming Phase II clinical trials. [48]

3.3. Recombinant Vector-Based Vaccines

3.3.1. MVA-BN-RSV/Ad26.RSV.preF

The recombinant vector-based vaccine MVA-BN-RSV from Bavarian Nordic uses the modified vaccinia Ankara virus altered to induce immunity against the F, G, N, and M2 proteins of RSV. [68] Recently, the company announced the withdrawal of the development of this vaccine from its pipeline because one of the primary outcomes of the Phase III clinical trial (NCT05238025) regarding vaccine efficacy was not achieved. [69] Previously, Janssen Pharmaceuticals stopped the further development of Ad26.RSV.preF in Phase III in the context of prioritizing the development of medicines for patients. [70] In Ad26.RSV.preF the Adenovirus 26 acted as the vector encoding the RSV F protein. [71]

3.3.2. RSV/Flu-01E

Following the discontinuation of MVA-BN-RSV and Ad26.RSV.preF, the Research Institute of Influenza in Russia announced a Phase I trial (NCT05970744) for a new recombinant vector-based vaccine candidate for RSV. RSV/Flu-01E uses influenza as the vector to encode the F protein of RSV. Results related to this study are yet not available.

4. Discussion

Comprehension of alterations related to the aging of the immune system guides the strategic design of vaccines, aiming to address the challenges of achieving a potent and safe vaccine. Vaccine platform and antigen selection play key roles in developing effective vaccines for specific age populations. Live-attenuated RSV vaccine candidates are predominantly designed for the pediatric population, as their efficacy tends to be less pronounced in older adults, [72] and the development of recombinant subunit, vector-based, conjugated, or mRNA vaccines is somewhat preferred for older adults. [73] The initiation of a vaccination schedule against a new pathogen in older adults is not indicated using live attenuated vaccines because of the linkage to a higher rate of adverse events. This observation highlights the significance of early administration of live attenuated vaccines at younger ages, combined with later booster dosages of vaccines based on inactivated or subunit platforms later in life. [74] The identification of the appropriate antigen or combination of antigens is also important for the success of a vaccination, especially in older adults. Based on the study results, antibodies that specifically recognize the preF conformation of the F protein exhibit higher efficacy than those targeting the post-F conformation. This observation led to the selection of the preF stabilized protein as an antigenic target for numerous new vaccines under development, optimizing the selection of antigens. It is supposed that mutations in RSV antigenic sites may diminish the efficacy of a vaccine encoding only these specific sites. Thus, including additional antigens, such as the G protein, seems a viable option to optimize the host immune responses to the virus. [75] Regarding the antigen of interest, dose selection is also of great importance for the resulting immunity. A high-dose antigen can significantly boost the titers of specific antibodies. Furthermore, an immunization schedule incorporating repeated vaccinations assists in establishing a long-lasting immunity. Different administration routes are also tested, such as the intradermal route, with the additional advantage of skin antigen-presenting cell function for the presentation of the antigens. [76] Adjuvant use in the vaccine formulation is another strategy to enhance the host's immunity against the co-administrated antigen. [77] Aluminum salts and MF59, an oil-in-water emulsion, are commonly added as immunostimulators in developing vaccines. [76] It seems that a targeted vaccine development for this specific population may overcome the impairment of the aging immune system. [17]
An estimation model was designed to assess the potential impact of RSV disease in the United States, considering hypothetical vaccination. According to the estimation, approximately 2.0 million individuals 60 years or older could be protected with vaccination against clinically manifested RSV-associated acute respiratory illness. This corresponds to approximately 50% of the total annual cases estimated for older adults. [78] A separate economic model predicted the prevention of around one-third of the total cases of RSV-associated hospitalizations and deaths in the United States for the elderly with an RSV vaccination. [79] According to the records retrieved from the Respiratory Syncytial Virus-Associated Hospitalization Surveillance Network for the period spanning July 2022 to June 2023, more than half of the older adults necessitating hospitalization due to RSV infection were 75 years of age or older. Among this demographic, clinical comorbidities were prevalent, contributing to an elevated demand for intensive care and interventional ventilation. Furthermore, individuals of younger age from diverse ethnic backgrounds exhibited heightened vulnerability to the disease, suggesting a varied age distribution across affected individuals. The decision for vaccination should be guided, considering these parameters for people aged 60 years or older. [80]
GSK’s and Pfizer’s RSV vaccines are publicly accessible for active immunization in adults aged 60 years or older. Positive outcomes derived from Phase III clinical trials indicate a minimum of moderate to higher efficacy rate in protecting against RSV-related LRTD for two RSV seasons. Currently, there is a lack of evidence regarding the vaccination’s impact on hospitalizations and mortality. Post-marketing studies should elucidate the safety of the vaccines, focusing specifically on adverse neurological events that were observed in preclinical trials. [81] The contribution of clinical assessment of the patient’s health status is important for the decision of vaccination against RSV in patients 60 years of age or older, according to the CDC. [82] An off-label immunization could be applied according to German organizations for individuals at high risk for the development of severe RSV disease, such as immunocompromised individuals or those with hematologic malignancies or burdened cardiopulmonary function. [83]. A cost-effectiveness analysis in the United States, considering the two approved vaccines, has estimated the impact of the vaccination, taking into account a coverage level similar to that seen with influenza vaccination. In this context, a decrease in the burden of the disease was estimated. Nevertheless, the real-world data may exhibit considerable variations, considering the inherent limitations of an economic model. [84] Another similar model also evaluated the impact of the two vaccines on older adults in Hong Kong. The vaccination with either one of the two available vaccines leads to the prevention of RSV cases, increasing the quality of life as evaluated in the economic cost-effectiveness study. The vaccine price and the incidence of RSV infections determine the outcomes in real-world data and shape the economic impact of vaccination strategies. [85] mRNA-1345 has shown positive outcomes in preclinical studies, and these findings have already been submitted for evaluation to obtain approval. Currently, three candidates have proceeded to Phase II clinical trials, and five vaccine candidates are in the early stage of development. Most vaccine candidates use the F protein as the target antigen, while various antigens are also being tested.
Undergoing the first RSV season, wherein two vaccines are available for the active immunization of the elderly, epidemiological, safety, and immunological data will contribute to meeting the criteria for safe and effective prevention against RSV in vulnerable populations. Post-marketing surveillance constitutes an integral component of this process and will assess the safety signals that emerged during the clinical trials. Targeted Phase III clinical trials have already evaluated the effect of coadministration of the RSV vaccines with vaccines targeting other respiratory viruses, as well as the responses in specific sub-groups at a heightened risk for severe RSV infection. The vaccination program will also be shaped based on the duration of the induced immunity and the costs of the vaccines, depending on the country. Various vaccines are under development for this vulnerable population, targeting different antigens using different vaccine types. The RSV vaccine landscape is a rapidly changing field as more vaccine developments are anticipated. The targeted development of vaccines tailored for the elderly, appropriately adjusted to the changes in their immune system, appears to yield successful outcomes.

Supplementary Materials

The following supporting information can be downloaded at: Preprints.org.

Author Contributions

Conceptualization, G.P.; methodology, X.T.; data curation, X.T.; writing—original draft preparation, X.T.; writing—review and editing, P.G, S.B, G.G; supervision, G.P and A.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing is not applicable.

Conflicts of Interest

P.G., S.B., and A.K. hold a patent for the rBCG-N-hRSV vaccine with Pontificia Universidad Católica de Chile (PCT/US2008/076682). G.P, X.T and G.G declare no conflicts of interest.

References

  1. Ageing and Health Available online: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=At this time the share,2050 to reach 426 million.
  2. Nikolich-Žugich, J. The Twilight of Immunity: Emerging Concepts in Aging of the Immune System. Nat. Immunol. 2018, 19, 10–19. [Google Scholar] [CrossRef]
  3. Lian, J.; Yue, Y.; Yu, W.; Zhang, Y. Immunosenescence: A Key Player in Cancer Development. J. Hematol. Oncol. 2020, 13, 151. [Google Scholar] [CrossRef]
  4. Lee, K.-A.; Flores, R.R.; Jang, I.H.; Saathoff, A.; Robbins, P.D. Immune Senescence, Immunosenescence and Aging. Front. Aging 2022, 3. [Google Scholar] [CrossRef]
  5. McElhaney, J.E.; Effros, R.B. Immunosenescence: What Does It Mean to Health Outcomes in Older Adults? Curr. Opin. Immunol. 2009, 21, 418–424. [Google Scholar] [CrossRef]
  6. Grubeck-Loebenstein, B.; Della Bella, S.; Iorio, A.M.; Michel, J.-P.; Pawelec, G.; Solana, R. Immunosenescence and Vaccine Failure in the Elderly. Aging Clin. Exp. Res. 2009, 21, 201–209. [Google Scholar] [CrossRef]
  7. FRANCESCHI, C.; BONAFÈ, M.; VALENSIN, S.; OLIVIERI, F.; DE LUCA, M.; OTTAVIANI, E.; DE BENEDICTIS, G. Inflamm-aging: An Evolutionary Perspective on Immunosenescence. Ann. N. Y. Acad. Sci. 2000, 908, 244–254. [Google Scholar] [CrossRef] [PubMed]
  8. Oh, S.J.; Lee, J.K.; Shin, O.S. Aging and the Immune System: The Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. Immune Netw. 2019, 19, 1–18. [Google Scholar] [CrossRef] [PubMed]
  9. Olivieri, F.; Prattichizzo, F.; Grillari, J.; Balistreri, C.R. Cellular Senescence and Inflammaging in Age-Related Diseases. Mediators Inflamm. 2018, 2018, 1–6. [Google Scholar] [CrossRef] [PubMed]
  10. Li, X.; Li, C.; Zhang, W.; Wang, Y.; Qian, P.; Huang, H. Inflammation and Aging: Signaling Pathways and Intervention Therapies. Signal Transduct. Target. Ther. 2023, 8, 239. [Google Scholar] [CrossRef] [PubMed]
  11. Crooke, S.N.; Ovsyannikova, I.G.; Poland, G.A.; Kennedy, R.B. Immunosenescence: A Systems-Level Overview of Immune Cell Biology and Strategies for Improving Vaccine Responses. Exp. Gerontol. 2019, 124, 110632. [Google Scholar] [CrossRef] [PubMed]
  12. Metcalf, T.U.; Cubas, R.A.; Ghneim, K.; Cartwright, M.J.; Grevenynghe, J. Van; Richner, J.M.; Olagnier, D.P.; Wilkinson, P.A.; Cameron, M.J.; Park, B.S.; et al. Global Analyses Revealed Age-related Alterations in Innate Immune Responses after Stimulation of Pathogen Recognition Receptors. Aging Cell 2015, 14, 421–432. [Google Scholar] [CrossRef]
  13. Goronzy, J.J.; Weyand, C.M. Understanding Immunosenescence to Improve Responses to Vaccines. Nat. Immunol. 2013, 14, 428–436. [Google Scholar] [CrossRef]
  14. Solana, R.; Tarazona, R.; Gayoso, I.; Lesur, O.; Dupuis, G.; Fulop, T. Innate Immunosenescence: Effect of Aging on Cells and Receptors of the Innate Immune System in Humans. Semin. Immunol. 2012, 24, 331–341. [Google Scholar] [CrossRef]
  15. Crooke, S.N.; Ovsyannikova, I.G.; Poland, G.A.; Kennedy, R.B. Immunosenescence and Human Vaccine Immune Responses. Immun. Ageing 2019, 16, 1–16. [Google Scholar] [CrossRef]
  16. Allen, J.C.; Toapanta, F.R.; Chen, W.; Tennant, S.M. Understanding Immunosenescence and Its Impact on Vaccination of Older Adults. Vaccine 2020, 38, 8264–8272. [Google Scholar] [CrossRef]
  17. Fulop, T.; Larbi, A.; Pawelec, G.; Cohen, A.A.; Provost, G.; Khalil, A.; Lacombe, G.; Rodrigues, S.; Desroches, M.; Hirokawa, K.; et al. Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change. Vaccines 2022, 10, 607. [Google Scholar] [CrossRef]
  18. Bektas, A.; Zhang, Y.; Wood, W.H.; Becker, K.G.; Madara, K.; Ferrucci, L.; Sen, R. Age-Associated Alterations in Inducible Gene Transcription in Human CD4+ T Lymphocytes. Aging (Albany. NY). 2013, 5, 18–36. [Google Scholar] [CrossRef] [PubMed]
  19. Schmitt, V.; Rink, L.; Uciechowski, P. The Th17/Treg Balance Is Disturbed during Aging. Exp. Gerontol. 2013, 48, 1379–1386. [Google Scholar] [CrossRef] [PubMed]
  20. Kogut, I.; Scholz, J.L.; Cancro, M.P.; Cambier, J.C. B Cell Maintenance and Function in Aging. Semin. Immunol. 2012, 24, 342–349. [Google Scholar] [CrossRef] [PubMed]
  21. Ng, T.W.Y.; Cowling, B.J.; Gao, H.Z.; Thompson, M.G. Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-Analysis. J. Infect. Dis. 2018. [Google Scholar] [CrossRef] [PubMed]
  22. Cadar, A.N.; Martin, D.E.; Bartley, J.M. Targeting the Hallmarks of Aging to Improve Influenza Vaccine Responses in Older Adults. Immun. Ageing 2023, 20, 23. [Google Scholar] [CrossRef]
  23. Recommended Vaccines for Adults Available online: https://www.cdc.gov/vaccines/adults/rec-vac/index.html.
  24. Hansen, C.L.; Chaves, S.S.; Demont, C.; Viboud, C. Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018. JAMA Netw. Open 2022, 5, e220527. [Google Scholar] [CrossRef]
  25. Thompson, W.W.; Shay, D.K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L.J.; Fukuda, K. Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States. JAMA 2003, 289, 179. [Google Scholar] [CrossRef]
  26. Zheng, Z.; Warren, J.L.; Shapiro, E.D.; Pitzer, V.E.; Weinberger, D.M. Estimated Incidence of Respiratory Hospitalizations Attributable to RSV Infections across Age and Socioeconomic Groups. Pneumonia 2022, 14, 6. [Google Scholar] [CrossRef]
  27. Topalidou, X.; Kalergis, A.M.; Papazisis, G. Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines. Pathogens 2023, 12, 1259. [Google Scholar] [CrossRef]
  28. Chen, G.L.; Mithani, R.; Kapoor, A.; Lu, S.; Asmar, L. El; Panozzo, C.A.; Shaw, C.A.; Stoszek, S.K.; August, A. 234. Safety and Immunogenicity of MRNA-1345, an MRNA-Based RSV Vaccine in Younger and Older Adult Cohorts: Results from a Phase 1, Randomized Clinical Trial. Open Forum Infect. Dis. 2022, 9. [Google Scholar] [CrossRef]
  29. Moderna Announces MRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults Available online: https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults/default.aspx.
  30. Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and HMPV in Older Adults Available online: https://investors.icosavax.com/news-releases/news-release-details/icosavax-announces-positive-topline-interim-phase-1-results.
  31. Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and HMPV in Older Adults Available online: https://ir.icosavax.com/news-releases/news-release-details/icosavax-announces-positive-topline-interim-phase-2-results.
  32. Langley, J.M.; Macdonald, L.D.; Weir, G.M.; Mackinnon-Cameron, D.; Ye, L.; Mcneil, S.; Schepens, B.; Saelens, X.; Stanford, M.M.; Halperin, S.A. A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented with a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. J. Infect. Dis. 2018, 218, 378–387. [Google Scholar] [CrossRef]
  33. Ruckwardt, T.J.; Morabito, K.M.; Phung, E.; Crank, M.C.; Costner, P.J.; Holman, L.S.A.; Chang, L.A.; Hickman, S.P.; Berkowitz, N.M.; Gordon, I.J.; et al. Safety, Tolerability, and Immunogenicity of the Respiratory Syncytial Virus Prefusion F Subunit Vaccine DS-Cav1: A Phase 1, Randomised, Open-Label, Dose-Escalation Clinical Trial. Lancet Respir. Med. 2021, 9, 1111–1120. [Google Scholar] [CrossRef] [PubMed]
  34. Leroux-Roels, I.; Davis, M.G.; Steenackers, K.; Essink, B.; Vandermeulen, C.; Fogarty, C.; Andrews, C.P.; Kerwin, E.; David, M.-P.; Fissette, L.; et al. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. J. Infect. Dis. 2023, 227, 761–772. [Google Scholar] [CrossRef] [PubMed]
  35. Kotb, S.; Haranaka, M.; Folschweiller, N.; Nakanwagi, P.; Verheust, C.; De Schrevel, N.; David, M.P.; Mesaros, N.; Hulstrøm, V. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine in Older Japanese Adults: A Phase I, Randomized, Observer-Blind Clinical Trial. Respir. Investig. 2023, 61, 261–269. [Google Scholar] [CrossRef] [PubMed]
  36. Leroux-Roels, I.; Van Ranst, M.; Vandermeulen, C.; Abeele, C. Vanden; De Schrevel, N.; Salaun, B.; Verheust, C.; David, M.-P.; Kotb, S.; Hulstrøm, V. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study. J. Infect. Dis. 2023, 61, 261–269. [Google Scholar] [CrossRef] [PubMed]
  37. Schwarz, T.F.; Hwang, S.-J.; Ylisastigui, P.P.; Liu, C.-S.; Takazawa, K.; Yono, M.; Ervin, J.E.; Andrews, C.; Fogarty, C.; Eckermann, T.; et al. 96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic When Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination. Open Forum Infect. Dis. 2022, 9. [Google Scholar] [CrossRef]
  38. FULL PRESCRIBING INFORMATION AREXVY Available online: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Arexvy/pdf/AREXVY.PDF.
  39. Papi, A.; Ison, M.G.; Langley, J.M.; Lee, D.-G.; Leroux-Roels, I.; Martinon-Torres, F.; Schwarz, T.F.; van Zyl-Smit, R.N.; Campora, L.; Dezutter, N.; et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N. Engl. J. Med. 2023, 388, 595–608. [Google Scholar] [CrossRef] [PubMed]
  40. Falsey, A.R.; Walsh, E.E.; Scott, D.A.; Gurtman, A.; Zareba, A.; Jansen, K.U.; Gruber, W.C.; Dormitzer, P.R.; Swanson, K.A.; Jiang, Q.; et al. Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine. J. Infect. Dis. 2022, 225, 2056–2066. [Google Scholar] [CrossRef] [PubMed]
  41. Walsh, E.E.; Falsey, A.R.; Scott, D.A.; Gurtman, A.; Zareba, A.M.; Jansen, K.U.; Gruber, W.C.; Dormitzer, P.R.; Swanson, K.A.; Radley, D.; et al. A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine. J. Infect. Dis. 2022, 225, 1357–1366. [Google Scholar] [CrossRef] [PubMed]
  42. Schmoele-Thoma, B.; Zareba, A.M.; Jiang, Q.; Maddur, M.S.; Danaf, R.; Mann, A.; Eze, K.; Fok-Seang, J.; Kabir, G.; Catchpole, A.; et al. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. N. Engl. J. Med. 2022, 386, 2377–2386. [Google Scholar] [CrossRef] [PubMed]
  43. Walsh, E.E.; Pérez Marc, G.; Zareba, A.M.; Falsey, A.R.; Jiang, Q.; Patton, M.; Polack, F.P.; Llapur, C.; Doreski, P.A.; Ilangovan, K.; et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N. Engl. J. Med. 2023, 388, 1465–1477. [Google Scholar] [CrossRef]
  44. RESPIRATORY SYNCYTIAL VIRUS STABILIZED BIVALENT PREFUSION F SUBUNIT VACCINE (RSVPREF / ABRYSVO) Available online: https://www.fda.gov/media/165625/download.
  45. Athan, E.; Baber, J.; Quan, K.; Scott, R.J.; Jaques, A.; Jiang, Q.; Li, W.; Cooper, D.; Cutler, M.W.; Kalinina, E. V; et al. Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults. Clin. Infect. Dis. 2023, 1–9. [Google Scholar] [CrossRef]
  46. Spearman, P.; Jin, H.; Knopp, K.; Xiao, P.; Gingerich, M.C.; Kidd, J.; Singh, K.; Tellier, M.; Radziewicz, H.; Wu, S.; et al. Intranasal Parainfluenza Virus Type 5 (PIV5)–Vectored RSV Vaccine Is Safe and Immunogenic in Healthy Adults in a Phase 1 Clinical Study. Sci. Adv. 2023, 9, eadj7611. [Google Scholar] [CrossRef]
  47. Abarca, K.; Rey-Jurado, E.; Muñoz-Durango, N.; Vázquez, Y.; Soto, J.A.; Gálvez, N.M.S.; Valdés-Ferrada, J.; Iturriaga, C.; Urzúa, M.; Borzutzky, A.; et al. Safety and Immunogenicity Evaluation of Recombinant BCG Vaccine against Respiratory Syncytial Virus in a Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. EClinicalMedicine 2020, 27. [Google Scholar] [CrossRef]
  48. Pacheco, G.A.; Andrade, C.A.; Gálvez, N.M.S.; Vázquez, Y.; Rodríguez-Guilarte, L.; Abarca, K.; González, P.A.; Bueno, S.M.; Kalergis, A.M. Characterization of the Humoral and Cellular Immunity Induced by a Recombinant BCG Vaccine for the Respiratory Syncytial Virus in Healthy Adults. Front. Immunol. 2023, 14, 1–12. [Google Scholar] [CrossRef] [PubMed]
  49. Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345 Available online: https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Global-Regulatory-Submissions-For-Its-Respiratory-Syncytial-Virus-RSV-Vaccine-MRNA-1345/default.aspx.
  50. Torrey, H.L.; Kaliaperumal, V.; Bramhecha, Y.; Weir, G.M.; Falsey, A.R.; Walsh, E.E.; Langley, J.M.; Schepens, B.; Saelens, X.; Stanford, M.M. Evaluation of the Protective Potential of Antibody and T Cell Responses Elicited by a Novel Preventative Vaccine towards Respiratory Syncytial Virus Small Hydrophobic Protein. Hum. Vaccines Immunother. 2020, 16, 2007–2017. [Google Scholar] [CrossRef] [PubMed]
  51. Cheng, X.; Zhao, G.; Dong, A.; He, Z.; Wang, J.; Jiang, B.; Wang, B.; Wang, M.; Huai, X.; Zhang, S.; et al. A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18–45 Years of Age. Vaccines 2023, 11, 999. [Google Scholar] [CrossRef] [PubMed]
  52. Subunit Vaccine (RSV Preventive Vaccine) ADV110 Available online: http://dev.vn.euroland.com:8129/en/pipeline-page/pipeline/#ADV110.
  53. Crank, M.C.; Ruckwardt, T.J.; Chen, M.; Morabito, K.M.; Phung, E.; Costner, P.J.; Holman, L.A.; Hickman, S.P.; Berkowitz, N.M.; Gordon, I.J.; et al. A Proof of Concept for Structure-Based Vaccine Design Targeting RSV in Humans. Science (80-. ). 2019, 365, 505–509. [Google Scholar] [CrossRef] [PubMed]
  54. Flynn, J.A.; Durr, E.; Swoyer, R.; Cejas, P.J.; Horton, M.S.; Galli, J.D.; Cosmi, S.A.; Espeseth, A.S.; Bett, A.J.; Zhang, L. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein. PLoS One 2016, 11, 1–18. [Google Scholar] [CrossRef] [PubMed]
  55. Sastry, M.; Zhang, B.; Chen, M.; Joyce, M.G.; Kong, W.P.; Chuang, G.Y.; Ko, K.; Kumar, A.; Silacci, C.; Thom, M.; et al. Adjuvants and the Vaccine Response to the DS-Cav1-Stabilized Fusion Glycoprotein of Respiratory Syncytial Virus. PLoS One 2017, 12, 1–21. [Google Scholar] [CrossRef] [PubMed]
  56. Che, Y.; Gribenko, A. V.; Song, X.; Handke, L.D.; Efferen, K.S.; Tompkins, K.; Kodali, S.; Nunez, L.; Prasad, A.K.; Phelan, L.M.; et al. Rational Design of a Highly Immunogenic Prefusion-Stabilized F Glycoprotein Antigen for a Respiratory Syncytial Virus Vaccine. Sci. Transl. Med. 2023, 15. [Google Scholar] [CrossRef]
  57. Joyce, M.G.; Zhang, B.; Ou, L.; Chen, M.; Chuang, G.-Y.; Druz, A.; Kong, W.-P.; Lai, Y.-T.; Rundlet, E.J.; Tsybovsky, Y.; et al. Iterative Structure-Based Improvement of a Fusion-Glycoprotein Vaccine against RSV. Nat. Struct. Mol. Biol. 2016, 23, 811–820. [Google Scholar] [CrossRef]
  58. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine.
  59. Arexvy Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy.
  60. Medicines and Healthcare Products Regulatory Agency Authorises GSK’s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults Available online: https://www.gsk.com/en-gb/media/press-releases/medicines-and-healthcare-products-regulatory-agency-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/#:~:text=The MHRA has authorised Arexvy,aged 60 years and older.
  61. ABRYSVO-HIGHLIGHTS OF PRESCRIBING INFORMATION Available online: https://labeling.pfizer.com/ShowLabeling.aspx?id=19589#section-9.
  62. Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVOTM for RSV Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-broadens-portfolio-respiratory-vaccines-recommended.
  63. Respiratory Syncytial Virus (RSV) Available online: https://www.bluelakebiotechnology.com/our-pipeline.
  64. Blue Lake Biotechnology Announces FDA Fast Track Designation for BLB-201 Intranasal RSV Vaccine Available online: https://www.prnewswire.com/news-releases/blue-lake-biotechnology-announces-fda-fast-track-designation-for-blb-201-intranasal-rsv-vaccine-301553567.html.
  65. Díaz, F.E.; Guerra-Maupome, M.; McDonald, P.O.; Rivera-Pérez, D.; Kalergis, A.M.; McGill, J.L. A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus. Front. Immunol. 2021, 12, 664212. [Google Scholar] [CrossRef]
  66. Céspedes, P.F.; Rey-Jurado, E.; Espinoza, J.A.; Rivera, C.A.; Canedo-Marroquín, G.; Bueno, S.M.; Kalergis, A.M. A Single, Low Dose of a CGMP Recombinant BCG Vaccine Elicits Protective T Cell Immunity against the Human Respiratory Syncytial Virus Infection and Prevents Lung Pathology in Mice. Vaccine 2017, 35, 757–766. [Google Scholar] [CrossRef]
  67. Rey-Jurado, E.; Bohmwald, K.; Correa, H.G.; Kalergis, A.M. TCR Repertoire Characterization for T Cells Expanded in Response to HRSV Infection in Mice Immunized with a Recombinant BCG Vaccine. Viruses 2020, 12. [Google Scholar] [CrossRef]
  68. Samy, N.; Reichhardt, D.; Schmidt, D.; Chen, L.M.; Silbernagl, G.; Vidojkovic, S.; Meyer, T.P.; Jordan, E.; Adams, T.; Weidenthaler, H.; et al. Safety and Immunogenicity of Novel Modified Vaccinia Ankara-Vectored RSV Vaccine: A Randomized Phase I Clinical Trial. Vaccine 2020, 38, 2608–2619. [Google Scholar] [CrossRef]
  69. BAVARIAN NORDIC PROVIDES UPDATE ON RSV VACCINE PROGRAM Available online: https://www.bavarian-nordic.com/investor/news/news.aspx?news=6808.
  70. Janssen Provides Portfolio Update Available online: https://www.jnj.com/janssen-provides-portfolio-update.
  71. Williams, K.; Bastian, A.R.; Feldman, R.A.; Omoruyi, E.; de Paepe, E.; Hendriks, J.; van Zeeburg, H.; Godeaux, O.; Langedijk, J.P.M.; Schuitemaker, H.; et al. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.PreF) in Adults Aged ≥60 Years. J. Infect. Dis. 2020, 222, 979–988. [Google Scholar] [CrossRef]
  72. Stephens, L.M.; Varga, S.M. Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population. Vaccines 2021, 9, 624. [Google Scholar] [CrossRef]
  73. Soegiarto, G.; Purnomosari, D. Challenges in the Vaccination of the Elderly and Strategies for Improvement. Pathophysiology 2023, 30, 155–173. [Google Scholar] [CrossRef]
  74. Weinberger, B.; Herndler-Brandstetter, D.; Schwanninger, A.; Weiskopf, D.; Grubeck-Loebenstein, B. Biology of Immune Responses to Vaccines in Elderly Persons. Clin. Infect. Dis. 2008, 46, 1078–1084. [Google Scholar] [CrossRef]
  75. Jenkins, V.A.; Hoet, B.; Hochrein, H.; De Moerlooze, L. The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein. Vaccines 2023, 11, 382. [Google Scholar] [CrossRef]
  76. Boraschi, D.; Italiani, P. Immunosenescence and Vaccine Failure in the Elderly: Strategies for Improving Response. Immunol. Lett. 2014, 162, 346–353. [Google Scholar] [CrossRef] [PubMed]
  77. Wagner, A.; Weinberger, B. Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. Front. Immunol. 2020, 11, 1–20. [Google Scholar] [CrossRef] [PubMed]
  78. Van Effelterre, T.; Hens, N.; White, L.J.; Gravenstein, S.; Bastian, A.R.; Buyukkaramikli, N.; Cheng, C.Y.; Hartnett, J.; Krishnarajah, G.; Weber, K.; et al. Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model. Clin. Infect. Dis. 2023, 77, 480–489. [Google Scholar] [CrossRef] [PubMed]
  79. Herring, W.L.; Zhang, Y.; Shinde, V.; Stoddard, J.; Talbird, S.E.; Rosen, B. Clinical and Economic Outcomes Associated with Respiratory Syncytial Virus Vaccination in Older Adults in the United States. Vaccine 2022, 40, 483–493. [Google Scholar] [CrossRef]
  80. Havers, F.P.; Whitaker, M.; Melgar, M.; Chatwani, B.; Chai, S.J.; Alden, N.B.; Meek, J.; Openo, K.P.; Ryan, P.A.; Kim, S.; et al. Characteristics and Outcomes Among Adults Aged ≥60 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus — RSV-NET, 12 States, July 2022–June 2023. Am. J. Transplant. 2023, 23, 2000–2007. [Google Scholar] [CrossRef]
  81. Melgar, M.; Britton, A.; Roper, L.E.; Talbot, H.K.; Long, S.S.; Kotton, C.N.; Havers, F.P. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. Am. J. Transplant. 2023, 23, 1631–1640. [Google Scholar] [CrossRef] [PubMed]
  82. RSV Vaccination for Older Adults 60 Years of Age and Over Available online: https://www.cdc.gov/vaccines/vpd/rsv/public/older-adults.html.
  83. Addo, M.; Cornely, O.; Denkinger, M.; Ertl, G.; Herold, S.; Pletz, M.; Rohde, G.; Welte, T.; Windisch, W.; Witzenrath, M. RSV Vaccination Strategies for High-Risk Patients 2023: A Collaborative Position Paper by Leading German Medical Societies and Organizations. Infection 2023, 1–4. [Google Scholar] [CrossRef] [PubMed]
  84. Moghadas, S.M.; Shoukat, A.; Bawden, C.E.; Langley, J.M.; Singer, B.H.; Fitzpatrick, M.C.; Galvani, A.P. Cost-Effectiveness of Prefusion F Protein-Based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States. Clin. Infect. Dis. 2023, 1–9. [Google Scholar] [CrossRef] [PubMed]
  85. Wang, Y.; Fekadu, G.; You, J.H.S. Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong. Vaccines 2023, 11, 1605. [Google Scholar] [CrossRef]
Table 1. Respiratory Syncytial Virus Vaccines: Clinical trials in adults over 50 years of age.
Table 1. Respiratory Syncytial Virus Vaccines: Clinical trials in adults over 50 years of age.
Vaccine Technology Vaccine candidate Manufacturer Clinical trial (Phase) Population Outcome
mRNA mRNA-1345 Moderna, Inc. NCT04528719 (I) ≥18 to ≤49 years
≥65 to <80 years
Japanese adults ≥ 60 years
(Included also women and children)		 Geometric mean fold rise (GMFR) one-month post-vaccination for the older adult participants: 12.1-16.6 for RSV-A and 8.7-12.6 for RSV-B neutralizing antibodies (nAbs).
Similar levels for the PreF binding antibodies. Results analogous to those of the younger adults [28].
NCT05397223 (I) 18-75 years Active trial.
Tests mRNA vaccines against SARS-CoV-2, seasonal influenza, respiratory syncytial virus (RSV), cytomegalovirus.
NCT05585632 (I) 50-75 years Active trial.
Tests multi-component vaccines against influenza, RSV and SARS-CoV-2.
NCT05585632 (I) 50-75 years Active trial.
Tests multi-component mRNA vaccines against influenza, RSV, and SARS-CoV2.
ConquerRSV NCT05127434 (II/III) ≥60 years Vaccine efficacy (VE) against RSV-low respiratory tract diesease (LRTD)
  • manifested with ≥2 clinical symptoms: 83.7%.
  • manifested with ≥3 clinical symptoms: 82.4%.
New analyses from the study are expected [29].
RSVictory
NCT05330975 (III)		 ≥50 years Active trial.
Co-administration with seasonal influenza vaccine or SARS-CoV-2 vaccine.
NCT06067230 (III) ≥18 years with high-risk comorbidities Currently enrolling participants.
NCT06060457 (III) ≥65 years Currently enrolling participants.
Co-administration with quadrivalent seasonal influenza vaccine.
NCT06060457 (III) ≥65 years Currently enrolling participants.
Co-administration with high-dose quadrivalent seasonal influenza vaccine.
RSV mRNA LNP CL-0059 or LNP CL-0137 Sanofi Pasteur
(a Sanofi Company)		 NCT05639894 (I/II) 18-50 years
≥60 years		 Active trial.
Subunit and Viral-like-particle-based vaccines IVX-A12
(RSV and hMPV)		 Icosavax, Inc. NCT05664334 (I) 60-75 years Geometric mean titers (GMTs) one-month post-vaccination: sixfold increase for RSV-A and threefold increase for RSV-B nAbs
GMFR: 4-fold for RSV-A and 3-fold for RSV-B
Analogous results for human metapneumovirus (hMPV) titers [30].
NCT05903183 (II) 60-85 years Interim data: GMTs: approximately sixfold elevation for RSV-A nAbs and fourfold elevation for RSV-B nAbs [31].
DPX-RSV(A) Immunovaccine Technologies, Inc. NCT02472548 (I) 50-64 years Encouraging immunogenicity outcomes for this novel antigen (RSV-A SHe).
GMTR
  • two months post-vaccination: 10-fold increase
  • day 236: a nearly 100-fold increase
The Alum formulation did not exhibit these immunogenicity results.
Duration up to 180 days after the second vaccine dose. Humoral immunity activation comparable to that after natural exposure [32].
VN-0200 (undefined antigen and adjuvant) Daiichi Sankyo Co. NCT04914520 (I) ≥20 and ≤50 years
≥65 and ≤80 years
(Japan)		 Completed trial with no published results.
NCT05547087 (II) 60-80 years (Japan) Active trial.
BARS13 (ADV110) Advaccine Biopharmaceuticals Co. NCT04851977 (I) 18-45 years Dose-dependent induction of RSV-G specific antibodies [32].
NCT04681833 (II) 60-80 years Active trial
DS-Cav1 National Institute of Allergy and Infectious Diseases (NIAID) NCT03049488 (I) 18-50 years Dose-dependent production of nAbs against both strains until week 44, including induction of mucosal immunity. Modifications are being investigated [33].
Arexvy™ GlaxoSmithKline plc. (GSK plc.) NCT03814590 (I/II) 18-40 years
60-80 years		 Dose and adjuvant selection.
The high dose formulation induced analogous increases in specific nAb titers in older adults with the maximum effect after the first vaccination.
Elevation of geometric mean frequencies (GMFs) of CD4+ T cells.
Duration: a year post-vaccination [34].
NCT04090658 (I) 60-80 years (Japan) Titers of specific IgG and nAb against both strains of RSV underwent alterations similar to those observed in the previous study [35].
NCT04657198 (II)
Extension trial of NCT03814590		 ≥60 years participating in the NCT03814590 trial Specific IgGs and nAbs notably increased after revaccination.
Further reactivation of CD4+ T-cell immunity.
Results supporting a revaccination schedule in the older adults [36].
NCT05921903 (IIb) ≥50 years at a high-risk for RSV-LRTD Currently enrolling participants.
NCT04732871 (III) ≥60 years Results until month 6.
High measured levels of humoral and cellular immunity, lasting above baseline [37].
NCT04841577 (III) ≥60 years Co-administration with seasonal quadrivalent influenza vaccine
It was demonstrated that the co-administration is equally effective as the separate administration of the two vaccines with a one-month interval [38].
NCT04886596 (III) ≥60 years VE against RSV-LRTD: 82.6%.
VE against severe RSV-LRTD: 94.1%.
VE against ≥1 case of RSV-acute respiratory infection (ARI): 71.7%.
VE in the age group of 70-79 years: 93.8%.
VE for vaccines with pre-existing frailty: 92.9%.
VE for participants with comorbidities: 94.6%.
The study remains in progress [39].
NCT05059301 (III) ≥60 years Study of 3 different lots of the vaccine.
Immunity was elicited at comparable levels across different lots.
NCT05559476 (III) ≥65 years Co-administration with high dose quadrivalent influenza vaccine.
Study completed without published results.
NCT05568797 (III) ≥65 years Co-administration with an adjuvanted inactivated influenza vaccine.
Study completed without published results.
NCT05590403 (III) 50-59 years at high risk for RSV disease and ≥60 years Active trial
NCT05966090 (III) ≥50 years Active trial.
Co-administration trial with Herpes zoster recombinant subunit vaccine.
NCT05879107 (III) ≥60 years Active trial.
Co-administration trial with the 20-valent pneumococcal conjugate vaccine (PCV20).
Abrysvo™ Pfizer Inc. NCT03529773 (I/II) 18-85 years Elevated Ab titers against both RSV strains and specific IgG titers, overcoming baseline until 12 months.
Similar distribution of results between the two groups [40,41].
NCT05788237 (Ib) ≥50 years Co-administration with influenza vaccine.
Study completed with no released results.
NCT04785612 (II) 18-50 years RSV challenge trial.
Vaccine effective against manifestation of clinical symptoms associated with RSV disease [42].
NCT05886777 (II) ≥65 years Active trial.
Tests vaccination against COVID-19, RSV, and influenza as either combined or separate vaccinations.
RENOIR/ NCT05035212 (III) ≥60 years Interim data.
VE: 66.7% in preventing RSV-related lower respiratory tract infection (LRTI) with ≥2 symptoms and 85.7% for cases of illness with ≥3 symptoms.
VE against RSV-ARI: 62.1%.
Duration: entire RSV season.
No differences in specific analyses between individuals 60-69 years, 70-79 years, ≥80 years and those at high-risk for illness [43].
NCT05096208 (III) 18-49 years Tested 3 different lots of the vaccine formulation and demonstrated comparability of the immune responses [44].
NCT05301322 (III) ≥65 years Co-administration with seasonal inactivated influenza vaccine.
Immunity induction was non-inferior after the co-administration of the two vaccines compared to the separate administration [45].
MONET/
NCT05842967 (III)		 ≥18 years at high-risk condition for severe illness Active trial.
NCT06077968 Population Retrospective trial based on the real-world healthcare data.
Arexvy + Abrysvo
(University of Rochester)		 NCT06077149 (IV) ≥60 years Recently posted.
Tests the immune induction between older adults residing in long-term care facilities and the community.
BLB-201 Blue Lake Biotechnology, Inc. NCT05281263 (I) 18-59 and 60-75 years Boosted specific serum and mucosal antibody production in both groups, with mucosal immunity activation to a greater extend in younger adults (Suggestion of dose/administration adjustment for the elderly).
Strong elicitation of cytotoxic CD8+ T cell immunity in older adults [46].
rBCG-N-hRSV Pontificia Universidad Católica de Chile EVA-VRS01/
NCT03213405 (I)
 18-50 years Bivalent vaccine.
Elevated levels of Abs against both antigens, proportional to the dose increase.
Upcoming Phase II trial is planned [47,48].
Recombinant vector-based vaccine RSV/Flu-01E Research Institute of Influenza, Russia NCT05970744 (I) 18-59 and ≥60 years Active trial.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated